Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
PR91626
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire=KYODO JBN/--
Eleva, a manufacturer of superior biologics, is scaling up its production
capacity to 2500 l in state-of-the-art single-use reactors. This will produce
enough factor H to cover all three clinical phases.
Eleva has ordered four more state-of-the-art, 500 l single-use reactors from
Sartorius Stedim Systems. The scale-up will enable Eleva to enter clinical
development of factor H, a key component of a pathway of the immune system
known as alternative complement pathway.
The complement system enhances (complements) the body's ability to clear
microbes and damaged cells from an organism. Factor H regulates the activation
of that immune response and ensures the body's own cells are protected.
Insufficient regulation of the complement system leads to excessive
inflammation and potential tissue damage.
Factor H is a complex protein that only Eleva's moss-based platform has thus
far been able to yield in highest – human-like – quality. Eleva has been able
to demonstrate a significant reduction in tissue damage and inflammation in
animal models when its recombinant factor H was supplemented.
Ralf Smit, CBO: "Not only can we now produce sufficient amounts of our own drug
candidates for all clinical stages, but we are also in a position to offer
production capacity at industrial scale."
While Eleva will be pursuing the development of its own pipeline products, it
is also open for joint projects with other pharmaceutical companies.
About Eleva
Based in Freiburg, Germany, Eleva develops novel biological therapies with its
pharmaceutical partners. The privately-held company leverages its unique
moss-based production platform to produce supreme biologics like antibodies,
replacement enzymes, or fusion toxins. Eleva has successfully developed drug
candidates into clinical phases.
Press contact
eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0
www.elevabiologics.com
Source: eleva GmbH
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。